Compass Therapeutics’ (CMPX) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Tuesday,RTT News reports. They currently have a $8.00 target price on the stock. Wedbush also issued estimates for Compass Therapeutics’ FY2028 earnings at $1.17 EPS.

Several other equities research analysts have also issued reports on the stock. Jefferies Financial Group increased their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Guggenheim began coverage on Compass Therapeutics in a research report on Monday, February 24th. They set a “buy” rating and a $12.00 price target for the company. D. Boral Capital reiterated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Compass Therapeutics has an average rating of “Buy” and an average price target of $11.63.

Compass Therapeutics Trading Down 5.0 %

NASDAQ:CMPX opened at $1.61 on Tuesday. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08. The company’s 50 day moving average is $2.78 and its two-hundred day moving average is $2.10. The company has a market cap of $221.94 million, a PE ratio of -4.34 and a beta of 1.19.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its position in shares of Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares during the period. SG Americas Securities LLC increased its stake in Compass Therapeutics by 921.6% during the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after buying an additional 356,352 shares during the period. Geode Capital Management LLC boosted its position in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after buying an additional 19,095 shares during the period. Bleakley Financial Group LLC increased its position in shares of Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after acquiring an additional 28,589 shares during the period. Finally, Intech Investment Management LLC raised its stake in shares of Compass Therapeutics by 218.7% in the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after acquiring an additional 35,632 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.